TODAY: Gb Sciences’ President Demonstrates Effectiveness of Simplified Therapeutic Mixtures Inspired by Cannabis Plant Extracts at Canna Pharma 2022 Conference

Share This Post

Dr. Andrea Small-Howard discusses the company's novel process for developing disease-specific, cannabinoid-based therapeutics.

LAS VEGAS - October 13, 2022 - (Newswire.com)

Dr. Andrea Small-Howard, President and Chief Science Officer of Gb Sciences (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and drug development company, is demonstrating the potential efficacy of their proprietary cannabis-inspired mixtures today at the Canna Pharma 2022 Conference in San Diego, California. Dr. Small-Howard explains Gb Sciences' novel process for developing disease-specific, cannabinoid therapeutics in her presentation entitled "Case Studies: Identification of Minimum Essential Therapeutic Mixtures from Cannabis Plant Extracts by Screening in Cell and Animal Models." Gb Sciences' case studies include scientific evidence demonstrating the potential efficacy of their cannabinoid-based therapeutic mixtures designed to treat Parkinson's disease, chronic pain, or inflammation using their novel minimal essential mixture approach.

"Medicinal cannabis has shown great promise for the symptomatic treatment of many serious human disorders, but concerns around safety, consistency, legality, psychoactivity, and non-standardized routes of delivery, such as smoking and vaping, have slowed the adoption of the use of medical cannabis within traditional, physician-guided patient treatment programs. To address these challenges, we hypothesized that within Cannabis plant extracts, there would be a minimal essential mixture of compounds that preserves whole plant benefits, but with the manufacturing, quality control, and regulatory benefits of single ingredient therapies," said Dr. Andrea Small-Howard.

Minimal essential mixtures (MEM) is a term Gb Sciences has coined from their proprietary research after deeming that a simplified mixture represented a happy medium between whole plant medicines and single ingredient drugs. Minimum Essential Mixtures are designed to retain increased therapeutic effectiveness from molecular synergies within the original plant extracts, but with the manufacturing efficiencies, quality assurances, and regulatory advantages of single ingredient drugs. Gb Sciences' disease-specific MEM are produced for clinical evaluation using synthetic homologs of cannabis-based ingredients incorporated into sophisticated oral delivery modalities including Oral Dissolving Tablets (ODT), Oral Thin Films (OTF), time-released oral nanoparticles, and gel capsules to increase the stability, bioavailability, and ease-of-use of these ingredients relative to the non-standardized delivery methods used for Cannabis plant extracts.

Gb Sciences was recently published in Pharma's Almanac discussing the strategy behind their plant-inspired minimum essential mixtures, which provides context for the case studies being presented today.

To learn more about Gb Sciences, visit www.gbsciences.com.

About Gb Sciences and GbS Global Biopharma

Gb Sciences, Inc. is a plant-inspired, biopharmaceutical research and development company creating patented, disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary, GbS Global Biopharma, Inc. The 'plant-inspired' active ingredients in its therapeutic mixtures are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices. Gb Sciences' intellectual property portfolio contains six issued U.S. and three issued foreign patents, as well as 17 U.S. and 51 foreign patent-pending applications. In its drug development pipeline, Gb Sciences has five preclinical phase product development programs. Gb Sciences' lead program for Parkinson's disease is being prepared for a first-in-human clinical trial. Gb Sciences' formulations for chronic pain, anxiety, and depression are currently in preclinical animal studies with researchers at the National Research Council Canada. The company also received positive preclinical proof-of-concept data supporting its complex mixtures for the treatment of Cytokine Release Syndrome and its lead candidates will be optimized based on late-stage preclinical studies at Michigan State University. Gb Sciences' productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations. To learn more, visit www.gbsciences.com

Forward-Looking Statements

This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.


Contact Information:
Madeleine Moench
madeleine@newswire.com


Press Release Service by Newswire.com

Original Source: TODAY: Gb Sciences' President Demonstrates Effectiveness of Simplified Therapeutic Mixtures Inspired by Cannabis Plant Extracts at Canna Pharma 2022 Conference

Related Posts

FTC and DOJ File Statement of Interest in Hotel Room Algorithmic Price-Fixing Case

The Federal Trade Commission joined by the Justice Department’s...

FTC Releases 2023 Privacy and Data Security Update

The Federal Trade Commission released its Privacy and Data...

RedeemTV Announces New Documentary: ‘The Shroud Face to Face’

RedeemTV Announces New Documentary: ‘The Shroud Face to Face’
Company Logo

RedeemTV ? Streaming Goodness

Vision Video’s streaming platform RedeemTV is set to unveil the highly anticipated documentary The Shroud Face to Face on March 28, 2024.

The Shroud Face to Face, produced by The Nexus Institute and The Shroud LLC, is a captivating documentary that unravels the enigma of the Shroud of Turin. With cutting-edge technology and expert insights, the film provides a face-to-face encounter with this iconic relic, inviting audiences to delve into its history, authenticity, and the profound questions it raises.

This visually stunning film, based on the book The Shroud Face to Face by acclaimed author and filmmaker Robert Orlando, offers an immersive exploration of the centuries-old mystery surrounding the Shroud of Turin and has been endorsed with high praise.

"This is a compelling and convincing account of the single most fascinating relic in the Christian world. This is for anyone seeking to understand the significance and history of the Shroud of Turin.” — Bishop Robert Barron, founder of Word on Fire

'The Shroud Face to Face'

Watch Trailer: https://watch.redeemtv.com/trailer/the-shroud-trailer

RedeemTV is a FREE, donor-supported, Christian streaming platform with over 250,000 subscribers. Streaming more than 5,000 videos, it provides family-friendly content while continuing to spread the message of Jesus.

Vision Video is a leading DVD and film distributor, committed to bringing impactful and compelling stories to audiences worldwide. With a focus on cinematic excellence, Vision Video partners with filmmakers to showcase thought-provoking narratives that inspire and captivate.

The Nexus Media focuses on TV, motion pictures, books, and screenplays, along with award- winning documentaries and shorts. Our team has years of experience in media storytelling and developing well-crafted engaging content. We invite you to view some of our past projects, The Divine Plan and Silence Patton, and participate in our new initiatives.

Stream FREE on RedeemTV: https://redeemtv.com.

Find us on Facebook at https://www.facebook.com/RedeemTV.

Follow us on Instagram at https://www.instagram.com/redeemtv1.

Contact Information:
Danielle Tumminelli
Marketing & VOD Distribution Manager
danielle@visionvideo.com
484-750-2485


Original Source: RedeemTV Announces New Documentary: 'The Shroud Face to Face'
green agriculture project
- Part of VUGA Media group -best seo company